Holen Sie sich die Stockscreener-App
0.6838
5.03%
-0.0362
Handel nachbörslich:
.69
0.0062
+0.91%
Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten
D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Analyst Jason Kolbert Maintains 'Buy' Rating for Plus Therapeuti - GuruFocus
CNSide Diagnostics expands lab licenses to three more states - Investing.com
Plus Therapeutics Expands CNSide Assay Platform to State of California - The Manila Times
Plus Therapeutics (Nasdaq: PSTV) CNSide test now licensed in 48 states, reaching over 90% of U.S. - Stock Titan
Plus Therapeutics adds key personnel to CNSide Diagnostics team By Investing.com - Investing.com Canada
Plus Therapeutics (PSTV) Expands CNSide Diagnostics Team with Ke - GuruFocus
Plus Therapeutics adds key personnel to CNSide Diagnostics team - Investing.com
Plus Therapeutics Announces Key Hires to Strengthen Operations at CNSide Diagnostics, LLC - Quiver Quantitative
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - The Manila Times
Plus Therapeutics (Nasdaq: PSTV) expands CNSide team and issues new hire equity awards - Stock Titan
Why global investors buy Plus Therapeutics Inc. (XMP0) stockWeekly Investment Recap & Reliable Breakout Forecasts - Newser
Hines Adds 3 Life-Science Tenants at Levit Green - Realty News Report
Hines' Levit Green signs 3 biotech tenants for 30K-SF of lab and office space - The Business Journals
Plus Therapeutics Reports Positive Phase 1 Data for REYOBIQ in Leptomeningeal Metastases and Glioblastoma at WFNOS/SNO Annual Meeting - Quiver Quantitative
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - The Manila Times
Will Plus Therapeutics Inc. (XMP0) stock rise with strong economyTrade Ideas & Precise Buy Zone Tips - Newser
How Plus Therapeutics Inc. stock reacts to Fed rate cutsIPO Watch & Technical Entry and Exit Tips - Newser
Will Plus Therapeutics Inc. (XMP0) stock beat Nasdaq index returns2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Plus Therapeutics' (PSTV) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Aug Highlights: How Plus Therapeutics Inc. stock performs in weak economyMarket Sentiment Summary & Smart Allocation Stock Reports - BỘ NỘI VỤ
Will Plus Therapeutics Inc. stock gain from lower inflationTrade Signal Summary & High Accuracy Trade Alerts - Newser
How higher bond yields impact Plus Therapeutics Inc. (XMP0) stock2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - Newser
How dovish Fed policy supports Plus Therapeutics Inc. (XMP0) stock2025 Price Action Summary & Risk Controlled Daily Trade Plans - Newser
Why Plus Therapeutics Inc. stock is favored by top institutions - Newser
Plus Therapeutics (PSTV) Analyst Rating Update: Maintain Buy Rat - GuruFocus
Plus Therapeutics to present breast cancer treatment data at SABCS By Investing.com - Investing.com Nigeria
Plus Therapeutics to present breast cancer treatment data at SABCS - Investing.com
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - The Manila Times
Plus Therapeutics, Inc. Announces Abstract Acceptance for Spotlight Presentation at San Antonio Breast Cancer Symposium 2025 on Rhenium (186Re) obisbemeda for Leptomeningeal Metastases Treatment - Quiver Quantitative
Plus Therapeutics (NASDAQ: PSTV) lands SABCS 2025 spotlight for LM Phase 1 trial - Stock Titan
HC Wainwright Expects Weaker Earnings for Plus Therapeutics - MarketBeat
How Plus Therapeutics Inc. stock reacts to job market dataFed Meeting & Long Hold Capital Preservation Tips - moha.gov.vn
Plus Therapeutics Eyes Expansion Despite Wider Quarterly Loss - Finimize
Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 - Investing.com Nigeria
H.C. Wainwright reaffirms Buy rating on Plus Therapeutics stock at $2.00 By Investing.com - Investing.com India
PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus - ts2.tech
Plus Therapeutics completes FDA meeting on REYOBIQ cancer treatment - Investing.com India
Plus Therapeutics completes FDA meeting on REYOBIQ cancer treatment By Investing.com - Investing.com Nigeria
Plus Therapeutics (PSTV) Advances Reyobiq Development After FDA Meeting - GuruFocus
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times
Plus Therapeutics Announces Completion of U.S. FDA Meeting - GlobeNewswire
Plus Therapeutics Stock (PSTV) Opinions on Humana Coverage Agreement - Quiver Quantitative
Ascendiant Capital Markets Cuts Plus Therapeutics (NASDAQ:PSTV) Price Target to $19.00 - MarketBeat
Ascendiant Capital Maintains Plus Therapeutics (PSTV) Buy Recommendation - Nasdaq
Plus Therapeutics (PSTV) Maintains Buy Rating, Lowers Price Targ - GuruFocus
Will Plus Therapeutics Inc. (XMP0) stock outperform global peersWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):